WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
SNGX
SOLIGENIX INC
$4.37M$839.36k-$7.74M-$6.14M-$0.79-11.55%-30.67%N/AN/A2024-05-23
ADVM
ADVERUM BIOTECHNOLOGIES INC
$190.74M$3.60M-$99.57M-$117.17M-$11.60N/A17.43%N/AN/A2024-06-07
BHVN
BIOHAVEN LTD
$3.18B$0.00-$402.64M-$408.17M-$5.73N/AN/AN/AN/A2024-05-10
TOVX
THERIVA BIOLOGICS INC
$7.19M$0.00-$19.47M-$18.35M-$1.14N/AN/AN/AN/A2024-05-09
TPST
TEMPEST THERAPEUTICS INC
$78.56M$0.00-$25.96M-$29.49M-$1.91N/AN/AN/AN/A2024-06-13
AIM
AIM IMMUNOTECH INC
$21.36M$202.00k-$28.44M-$28.96M-$0.6043.26%-11.26%N/AN/A2024-05-13
ALNY
ALNYLAM PHARMACEUTICALS INC
$18.05B$1.83B-$215.27M-$440.24M-$3.5276.23%89.45%N/AN/A2024-05-16
XLO
XILIO THERAPEUTICS INC
$37.58M$0.00-$74.50M-$76.40M-$2.78N/AN/AN/AN/A2024-06-07
INBX
INHIBRX INC
$1.61B$1.80M-$206.56M-$241.36M-$5.12-17.88%-26.85%N/AN/A2024-05-24
PIRS
PIERIS PHARMACEUTICALS INC
$14.49M$42.81M-$22.76M-$24.54M-$21.6065.28%8.03%N/AN/A2024-06-20
CERE
CEREVEL THERAPEUTICS HOLDINGS INC
$7.71B$0.00-$416.15M-$432.84M-$2.67N/AN/AN/AN/A2024-06-06
REVB
REVELATION BIOSCIENCES INC
$3.56M$0.00-$95.21k-$120.25k-$0.53N/AN/AN/AN/A2024-05-20
PROK
PROKIDNEY CORP
$486.21M$0.00-$25.61M-$35.47M-$0.57N/AN/AN/AN/A2024-05-03
CGTX
COGNITION THERAPEUTICS INC
$76.05M$0.00-$25.51M-$25.79M-$0.86N/AN/AN/AN/A2024-05-04
CKPT
CHECKPOINT THERAPEUTICS INC
$51.03M$103.00k-$51.85M-$51.85M-$3.17-46.35%-50.61%N/AN/A2024-05-13
PTCT
PTC THERAPEUTICS INC
$2.19B$927.56M-$245.30M-$579.22M-$7.6820.39%28.74%N/AN/A2024-06-05
CGEN
COMPUGEN LTD
$169.76M$33.46MN/A-$18.75M-$0.21346.12%13.45%N/AN/A2024-05-13
CDMO
AVID BIOSERVICES INC
$466.58M$136.74M-$7.83M-$17.98M-$0.28-2.81%25.75%N/AN/A2024-06-19
MCRB
SERES THERAPEUTICS INC
$124.58M$126.33M-$85.43M-$113.72M-$0.891,672.24%34.91%N/AN/A2024-05-07
TRVN
TREVENA INC
$7.16M$3.13M-$35.99M-$40.29M-$3.16N/A-11.43%N/AN/A2024-06-13
CELU
CELULARITY INC
$58.52M$14.79M-$169.66M-$181.41M-$10.10-20.93%N/AN/AN/A2024-06-13
GYRE
GYRE THERAPEUTICS INC
$1.46B$113.45M-$82.99M-$92.93M-$1.4110.91%N/AN/AN/A2024-05-13
CYTK
CYTOKINETICS INC
$6.73B$7.53M-$486.05M-$526.24M-$5.45-92.04%-24.89%N/AN/A2024-05-15
KYTX
KYVERNA THERAPEUTICS INC
$666.99M$0.00-$56.75M-$60.37M-$89.61-100.00%N/AN/AN/A
OGEN
ORAGENICS INC
$4.62M$37.65k-$20.60M-$20.66M-$9.18-71.37%N/AN/AN/A2024-05-10
SMMT
SUMMIT THERAPEUTICS INC
$2.71B$0.00-$612.88M-$614.93M-$0.01-100.00%-100.00%N/AN/A2024-05-22
PXMD
PAXMEDICA INC
$5.48M$0.00-$18.28M-$18.29M-$11.00N/AN/AN/AN/A
COEP
COEPTIS THERAPEUTICS HOLDINGS INC
$12.09M$0.00-$20.16M-$21.27M-$0.83N/AN/AN/AN/A
NBSE
NEUBASE THERAPEUTICS INC
$1.64M$0.00-$12.55M-$13.73M-$7.70N/AN/AN/AN/A2024-05-13
PRTG
PORTAGE BIOTECH INC
$4.75M$0.00-$170.35M-$144.91M-$8.34N/AN/AN/AN/A2024-05-14
VSTM
VERASTEM INC
$237.27M$0.00-$83.34M-$87.37M-$3.96-100.00%-100.00%N/AN/A2024-05-23
PHIO
PHIO PHARMACEUTICALS CORP
$3.13M$0.00-$10.64M-$10.83M-$5.20N/A-100.00%N/AN/A2024-06-17
CDXS
CODEXIS INC
$187.01M$70.14M-$66.25M-$76.24M-$1.12-49.39%2.97%N/AN/A2024-06-12
ATXI
AVENUE THERAPEUTICS INC
$3.66M$0.00-$10.38M-$10.38M-$73.50N/AN/AN/AN/A2024-06-21
IMNN
IMUNON INC
$13.54M$0.00-$19.88M-$19.51M-$2.16-100.00%-100.00%N/AN/A2024-06-13
NAMS
NEWAMSTERDAM PHARMA CO NV
$1.96B$15.32M-$192.24M-$192.32M-$2.34-85.67%N/AN/AN/A2024-05-06
KALV
KALVISTA PHARMACEUTICALS INC
$454.79M$0.00-$107.49M-$108.30M-$3.13N/A-100.00%N/AN/A
VANI
VIVANI MEDICAL INC
$89.61M$0.00-$24.39M-$25.65M-$0.50N/A-100.00%N/AN/A2024-06-14
CYBN
CYBIN INC
$143.93M$0.00-$51.93M-$52.19M-$0.21N/AN/AN/AN/A2024-06-26
NBY
NOVABAY PHARMACEUTICALS INC
$2.38M$14.73M-$9.44M-$16.70M-$3.962.24%3.32%N/AN/A2024-05-28
TIL
INSTIL BIO INC
$68.94M$0.00-$145.48M-$156.09M-$24.00N/AN/AN/AN/A2024-05-09
MNPR
MONOPAR THERAPEUTICS
$11.49M$0.00-$8.40M-$8.40M-$0.61N/AN/AN/AN/A2024-05-09
AVBP
ARRIVENT BIOPHARMA INC
$471.97M$0.00-$69.33M-$69.33M-$32.38N/AN/AN/AN/A
BIOR
BIORA THERAPEUTICS INC
$19.04M$4.00k-$113.84M-$124.12M-$7.87-98.69%-87.44%N/AN/A2024-06-05
BCDA
BIOCARDIA INC
$10.08M$477.00k-$11.16M-$11.57M-$0.55-64.72%-5.26%N/AN/A2024-05-20
INDP
INDAPTUS THERAPEUTICS INC
$18.02M$0.00-$15.42M-$15.42M-$1.83N/AN/AN/AN/A2024-05-03
SAVA
CASSAVA SCIENCES INC
$965.65M$0.00-$95.69M-$97.22M-$2.32N/AN/AN/AN/A2024-05-09
FBLG
FIBROBIOLOGICS INC
$329.93M$0.00-$15.90M-$19.06M-$0.68N/AN/AN/AN/A
ANRO
ALTO NEUROSCIENCE INC
$381.21M$0.00-$34.28M-$36.31M-$9.73N/AN/AN/AN/A
NVCT
NUVECTIS PHARMA INC
$115.50M$0.00-$22.26M-$22.26M-$1.43N/AN/AN/AN/A2024-05-06
ELEV
ELEVATION ONCOLOGY INC
$176.12M$0.00-$45.64M-$45.70M-$1.34N/AN/AN/AN/A2024-05-02
APLM
APOLLOMICS INC
$40.27M$0.00-$171.77M-$172.60M-$2.32N/AN/AN/AN/A
CALC
CALCIMEDICA INC
$58.53M$0.00-$34.30M-$34.36M-$7.66N/AN/AN/AN/A2024-05-13
XRTX
XORTX THERAPEUTICS INC
$5.86M$0.00-$5.58M-$5.63M-$3.09N/AN/AN/AN/A2024-06-27
CARA
CARA THERAPEUTICS INC
$37.38M$20.97M-$115.58M-$118.51M-$2.19-49.92%9.26%N/AN/A2024-06-04
ESLA
ESTRELLA IMMUNOPHARMA INC
$37.34M$0.00-$8.36M-$8.36M-$2.90N/AN/AN/AN/A
INAB
IN8BIO INC
$45.02M$0.00-$27.51M-$30.01M-$1.00N/AN/AN/AN/A2024-05-10
MNMD
MIND MEDICINE (MINDMED) INC
$352.17M$0.00-$92.57M-$95.73M-$2.44N/AN/AN/AN/A2024-06-10
KOD
KODIAK SCIENCES INC
$172.23M$0.00-$234.53M-$260.49M-$4.97N/AN/AN/AN/A2024-06-04
NEXI
NEXIMMUNE INC
$4.62M$0.00-$30.78M-$32.34M-$30.82N/AN/AN/AN/A2024-05-16
BOLD
BOUNDLESS BIO INC
N/A$0.00-$46.12M-$49.43M-$40.65N/AN/AN/AN/A
LIXT
LIXTE BIOTECHNOLOGY HOLDINGS INC
$7.33M$0.00-$5.07M-$5.09M-$2.66N/AN/AN/AN/A2024-05-08
CNTX
CONTEXT THERAPEUTICS INC
$22.51M$0.00-$23.90M-$23.96M-$1.50N/AN/AN/AN/A2024-05-08
ASMB
ASSEMBLY BIOSCIENCES INC
$69.36M$0.00-$60.75M-$61.23M-$13.38N/A-100.00%N/AN/A2024-05-29
ANL
ADLAI NORTYE LTD
$506.87M$5.00M-$101.22M-$104.87M-$7.26N/AN/AN/AN/A
LCTX
LINEAGE CELL THERAPEUTICS INC
$214.93M$8.95M-$22.60M-$21.49M-$0.12-39.16%12.39%N/AN/A2024-06-11
SCPX
SCORPIUS HOLDINGS INC
$6.09M$6.99M-$36.93M-$45.22M-$1.741,789.60%3.84%N/AN/A2024-05-13
IMUX
IMMUNIC INC
$109.71M$0.00-$93.50M-$93.61M-$2.11N/AN/AN/AN/A2024-06-11
ALRN
AILERON THERAPEUTICS INC
$84.86M$0.00-$15.61M-$15.73M-$3.42N/AN/AN/AN/A2024-05-06
ADXN
ADDEX THERAPEUTICS LTD
$16.13M$1.83M-$11.01M-$11.73M-$0.1626.20%-22.11%N/AN/A2024-04-30
AKBA
AKEBIA THERAPEUTICS INC
$280.56M$194.62M-$4.05M-$51.93M-$0.28-33.46%-1.30%N/AN/A2024-06-06
VERA
VERA THERAPEUTICS INC
$2.16B$0.00-$94.07M-$95.99M-$2.25N/AN/AN/AN/A2024-05-15
KZIA
KAZIA THERAPEUTICS LTD
$9.75M$15.13kN/A-$10.33M-$0.371,041.43%-65.97%N/AN/A
MDGL
MADRIGAL PHARMACEUTICALS INC
$3.85B$0.00-$360.39M-$373.63M-$19.99N/AN/AN/AN/A2024-06-14
AGEN
AGENUS INC
$244.86M$156.31M-$134.25M-$245.97M-$13.8059.47%33.56%N/AN/A2024-05-07
VAXX
VAXXINITY INC
$14.83M$0.00-$54.00M-$56.93M-$0.45N/AN/AN/AN/A2024-06-19
TSVT
2SEVENTY BIO INC
$218.33M$100.39M-$207.29M-$217.57M-$4.429.72%12.96%N/AN/A2024-06-12
AVTX
AVALO THERAPEUTICS INC
$16.48M$1.92M-$27.96M-$31.54M-$114.00-89.34%-22.83%N/AN/A2024-05-02
GUTS
FRACTYL HEALTH INC
$320.78M$120.00k-$76.81M-$94.27M-$45.29N/AN/AN/AN/A
OMER
OMEROS CORP
$182.52M$0.00-$86.05M-$117.81M-$1.88N/A-100.00%N/AN/A2024-06-21
EVAX
EVAXION BIOTECH A
$15.84M$73.00k-$21.23M-$22.13M-$8.10N/AN/AN/AN/A2024-05-29
FGEN
FIBROGEN INC
$102.72M$147.75M-$258.77M-$284.23M-$2.924.99%-7.05%N/AN/A2024-06-05
BBIO
BRIDGEBIO PHARMA INC
$4.37B$9.30M-$551.39M-$643.20M-$3.95-88.02%N/AN/AN/A2024-06-21
NTRB
NUTRIBAND INC
$27.81M$2.09M-$4.92M-$5.28M-$0.672.17%66.58%N/AN/A2024-04-29
DARE
DARE BIOSCIENCE INC
$30.78M$2.81M-$30.07M-$30.16M-$0.35-71.92%N/AN/AN/A2024-06-05
CERO
CERO THERAPEUTICS HOLDINGS INC
$20.17M$0.00-$2.44M-$2.54M-$0.39N/AN/AN/AN/A
NCNA
NUCANA PLC
$8.46M$0.00-$40.33M-$35.43M-$16.99N/AN/AN/AN/A2024-05-15
GRI
GRI BIO INC
$1.37M$0.00-$10.95M-$13.04M-$28.25N/AN/AN/AN/A2024-05-13
SANA
SANA BIOTECHNOLOGY INC
$1.92B$0.00-$245.43M-$283.26M-$1.46N/AN/AN/AN/A2024-06-07
CTCX
CARMELL CORP
$40.22M$0.00-$14.47M-$16.12M-$1.46N/AN/AN/AN/A
PHGE
BIOMX INC
$19.33M$0.00-$22.87M-$26.17M-$0.51N/AN/AN/AN/A2024-06-19
ARWR
ARROWHEAD PHARMACEUTICALS INC
$2.74B$181.74M-$262.45M-$296.81M-$2.76-34.71%30.90%N/AN/A2024-05-09
BIVI
BIOVIE INC
$19.34M$0.00-$39.04M-$43.27M-$1.17N/AN/AN/AN/A2024-05-08
MBIO
MUSTANG BIO INC
$3.28M$0.00-$45.27M-$51.60M-$6.00N/AN/AN/AN/A2024-06-20
LBPH
LONGBOARD PHARMACEUTICALS INC
$710.26M$0.00-$54.42M-$54.42M-$2.39N/AN/AN/AN/A2024-05-23
ITRM
ITERUM THERAPEUTICS PLC
$27.43M$0.00-$34.58M-$38.37M-$2.96N/A-100.00%N/AN/A2024-05-10
WINT
WINDTREE THERAPEUTICS INC
$2.67M$0.00-$19.75M-$20.29M-$94.32N/A-100.00%N/AN/A2024-05-13
RNAZ
TRANSCODE THERAPEUTICS INC
$3.19M$0.00-$17.97M-$18.55M-$103.61N/AN/AN/AN/A
VINC
VINCERX PHARMA INC
$15.63M$0.00-$39.24M-$40.16M-$1.89N/AN/AN/AN/A2024-05-23
PMN
PROMIS NEUROSCIENCES INC
$37.54M$0.00-$12.99M-$13.21M-$1.07N/AN/AN/AN/A2024-05-13

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -29.72% over the past year, underperforming other biotech stocks by -8 percentage points.

Incyte has an average 1 year price target of $74.69, an upside of 44.53% from Incyte's current stock price of $51.68.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 23.08% have issued a Strong Buy rating, 23.08% have issued a Buy, 53.85% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -7.45% over the past year, overperforming other biotech stocks by 15 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 27.33% from Harmony Biosciences Holdings's current stock price of $29.32.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock return 2.42% over the past year, overperforming other biotech stocks by 25 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 169.03% from Voyager Therapeutics's current stock price of $7.62.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 15.1%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 57.38%, which is 42 percentage points higher than the biotech industry average of 15.1%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.08%, which is -14 percentage points lower than the biotech industry average of 15.1%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% eight times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.2% in the last day, and up 1.13% over the last week. Biodexa Pharmaceuticals was the among the top gainers in the biotechnology industry, gaining 79.31% yesterday.

Biodexa shares are trading higher after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has gained 2.42% in the past year. It has overperformed other stocks in the biotech industry by 25 percentage points.

2. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -20.21% in the past year. It has overperformed other stocks in the biotech industry by 2 percentage points.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 72 points higher than the biotech industry average of 14. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -29.72% in the past year. It has underperformed other stocks in the biotech industry by -8 percentage points.

Are biotech stocks a good buy now?

49.23% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 91.76% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 14.88x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.